| Name | Title | Contact Details |
|---|---|---|
Elias Nyankojo |
Vice President,Chief Information Security Officer | Profile |
Swing Therapeutics was founded in 2019 with the goal of developing digital treatments in disease areas where patients are not well-served, and where digital interventions may be effective.
Park Systems is a Santa Clara, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Arbor Biotechnologies is an early stage life sciences company pushing the boundaries of biodiscovery. Using artificial intelligence, genome sequencing, gene synthesis and high-throughput screening, we are accelerating the discovery of proteins...
Co-Founded by world-renowned mycologist Paul Stamets, MycoMedica, PBC is a life sciences company developing therapeutic drugs derived from fungi to help people live healthier, better lives.
Aura Biosciences is a clinical-stage biotechnology company developing virus-like drug conjugates (VDC), a novel class of therapies, for the treatment of multiple oncology indications. At Aura, our mission is to deliver meaningful therapeutic benefit to a range of cancer indications with high unmet need in which we believe we can establish a new standard of care. We are driven by our passion and commitment to science and the patients battling cancer who are relying on us to pioneer these new therapies. We are focusing the initial development of our VDC technology platform to treat tumors of high unmet need in ocular and urologic oncology. Belzupacap sarotalocan (bel-sar), our first VDC candidate, is being developed for the first-line treatment of early-stage choroidal melanoma, a rare disease with no drugs approved. Beyond early-stage choroidal melanoma, we are developing bel-sar in additional ocular oncology indications, including choroidal metastasis. Leveraging our VDCs` broad tumor targeting capabilities, we have also initiated a clinical program in non-muscle invasive bladder cancer, or NMIBC, our first non-ocular solid tumor indication.